Risk of developing certain malignancies is related to duration of immunosuppressive drug exposure in patients with rheumatic diseases.

In addition to any increased risk of malignancy that may be conferred by individual rheumatic diseases, there is a further risk of specific types of malignancy that is related to the duration of exposure to immunosuppressive drugs.